ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1759

Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study

Annalisa Montante1, Alicia Le Bras2, Benjamin Terrier3, Pascal Cohen3, Xavier Puéchal4, Alexandre Karras5, Philippe Ravaud6, Loïc Guillevin7 and Isabelle Durand-Zaleski8, 1UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 2UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 3Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 4Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 5Nephrology, HEGP, Paris, France, 6Hôpital Hôtel Dieu, Paris, France, 7Internal medicine, Cochin University Hospital, paris, France, 8UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ANCA, azathioprine, Economics, rituximab and vasculitis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 6, 2017

Session Title: Vasculitis Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s high cost, we conducted ancillary cost-utility and cost-effectiveness analyses.

Methods:

The multicenter, prospective, open-label randomized–controlled MAINRITSAN-1 trial included 115 patients in France between 2008 and 2012. We collected all hospital healthcare resources used: hospitalizations, consultations, drugs, tests. The costs of AAV-related inpatient and outpatient care were based on hospital codes. Quality of life was evaluated with the Medial Outcomes Study Short Form-36 questionnaire.

We calculated the incremental cost-utility (ICUR) and cost-effectiveness ratios (ICER) and their corresponding acceptability curves. Costs were assessed from the perspective of the French National Health Insurance, using 2016 reimbursement tariffs, expressed in euros. Deterministic sensitivity analyses assessed uncertainty over side effects and rituximab cost. Costs drivers were tested with a generalized linear model.

Results: Out of 115 patients enrolled in the trial, 3 were excluded from the economic study. The Table reports resource use and costs at trial month 28. Rituximab’s higher cost was partly offset by fewer relapses, side effects and follow-up expenses. The 28-month ICER was €13,092 per relapse avoided and the 28-month ICUR was €57,127/QALY. Relapses, side effects and renal impairment were major cost determinants.

Azathioprine

Rituximab

Mean(SD)

Median[IQR]

Mean(SD)

Median[IQR]

Inpatient stays, n

1.9(2.6)

1[0–2]

1.7(2.9)

1[0–2]

Length of stay (days)

14.1(24.1)

7[1–16]

12.1(13.6)

7[5–14]

Outpatient visits, n

3.5(4.9)

1[0–5]

6.3(2.8)

6[5–7]

Cost (€/patient)

Protocol drug

313(130)

337[(264–391]

6,035(165)

6,057[6,057–6,057]

Its administration

0

0[0–0]

2,467(1,076)

2,020[1,830–2,875]

Maintenance therapy

633(1,808)

0[0–0]

0(0)

0[0–0]

Relapses

2,547(4,748)

0[0–4,737]

724(3,537)

0[0–0]

Side effects

2,869(6,946)

0[0–2,523]

1,983(4,908)

0[0–2,531]

Follow-up

3,126(7,183)

636[0–3,254]

1,713(3,809)

0[0–2,426]

Outpatient visits

988(407)

1,069[770–1,314]

748(285)

615[614–669]

Total cost

10,476(10,558)

6,049[2,140–14,501]

13,617(7,946)

10,942[9,103–14,197]

Conclusion: Rituximab maintenance therapy is cost-effective to prevent AAV relapses.


Disclosure: A. Montante, None; A. Le Bras, None; B. Terrier, None; P. Cohen, None; X. Puéchal, None; A. Karras, None; P. Ravaud, None; L. Guillevin, None; I. Durand-Zaleski, None.

To cite this abstract in AMA style:

Montante A, Le Bras A, Terrier B, Cohen P, Puéchal X, Karras A, Ravaud P, Guillevin L, Durand-Zaleski I. Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/economic-evaluation-of-rituximab-versus-azathioprine-for-maintenance-treatment-of-anca-associated-vasculitis-a-prospective-multicenter-study/. Accessed March 7, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/economic-evaluation-of-rituximab-versus-azathioprine-for-maintenance-treatment-of-anca-associated-vasculitis-a-prospective-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.